Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)
Can you apply?
This grant is for research institutions, universities, and nonprofit organizations seeking to conduct basic biomedical research on genomic variants associated with human congenital anomalies. The R01 mechanism supports independent research projects led by experienced investigators. Applicants must have appropriate institutional affiliation and research capacity. The grant supports genomic screening, variant analysis, and functional validation work, but clinical trials are explicitly not allowed. Geographic scope is unlimited for domestic U.S. institutions and eligible international institutions. Researchers at all career stages from postdoctoral fellows to established investigators may apply, though senior investigators typically have stronger success rates. Both individual and collaborative research teams are eligible.
Program description
Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including human congenital anomalies (HCAs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric congenital anomalies cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of congenital anomaly-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.
Who can apply
Eligible applicants
How to apply
Application links
Required documents
- NIH Form SF-424 (Application for Federal Assistance)
- Project Narrative (typically 15 pages maximum)
- Specific Aims (one page maximum)
- Research Strategy (including significance, innovation, and approach)
- Preliminary Studies/Progress Report
- Budget and Budget Justification
- Biographical Sketches for all key personnel
- Current and Pending Support
- Letters of Support from collaborators (if applicable)
- Resource Sharing Plans (Data Management, genome data sharing requirements)
- Facilities and Other Resources documentation
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.865 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$1,073,967,938
-
$719,372,575
-
$276,059,721
-
$155,556,396
-
$155,482,198
-
$103,665,364
-
$74,151,078
-
$71,490,911
-
$52,238,426
-
$47,450,377
Top States by Funding
- WA 1 awards $1,074.0M
- NC 7 awards $921.5M
- MD 4 awards $493.9M
- MA 3 awards $190.0M
- PA 3 awards $145.1M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.865). How funding has trended year over year.
| 2024 | $1,282,226,682 | |
| 2025 | $1,333,391,690 | |
| 2026 est. | $184,920,723 |
FAQ
Who is eligible to apply for this R01 grant?
Research institutions, universities, and nonprofit organizations with staff capable of conducting genomic research are eligible. Applicants should have access to appropriate laboratory facilities and bioinformatics resources. Individuals must have appropriate research credentials and institutional affiliation.
What is the application deadline?
The deadline is January 7, 2028. Applications must be submitted by 5:00 PM ET on this date through NIH's electronic submission system (Grants.gov or eRA Commons).
What types of research activities are supported?
The grant supports genomic screening, variant identification, functional validation studies, and mechanistic research on congenital anomalies. Clinical trials, clinical testing, and direct patient studies are not allowed.
How competitive is this grant?
R01 grants from NIH are highly competitive, with typical success rates around 20-25%. Strong preliminary data, clear innovation, and experienced research teams are essential for competitiveness.
What is the typical funding range?
R01 grants typically provide $250,000 to $500,000 annually (modular budget up to $250,000 or justification for higher amounts), with project periods up to 5 years.
💡 Tips for applicants
- Establish strong preliminary data demonstrating proof-of-concept for your variant screening and validation approach before submission. NIH reviewers expect convincing evidence that your methods work.
- Build a collaborative team with complementary expertise in genomics, functional biology, and bioinformatics. Multi-disciplinary approaches are viewed favorably for this complex research area.
- Frame your research within the broader context of understanding congenital anomalies at the molecular level. Connect your work to clinical significance and potential impact on understanding human development.
- Develop a detailed and realistic experimental plan with specific milestones. Include contingency approaches for validation methods to demonstrate thorough scientific thinking.
- Follow NIH formatting guidelines precisely (page limits, font size, margins) and address all review criteria explicitly. Reviewer time is limited, so clear organization directly improves your score.
⚠️ Common mistakes
Applications frequently fail because they lack sufficient preliminary data showing the feasibility of proposed variant screening and validation approaches, or they include clinical trial components that are explicitly not allowed. Weak or overly ambitious experimental plans without realistic timelines and contingencies are also common reasons for rejection. Finally, applicants often underestimate the importance of demonstrating how their research will advance mechanistic understanding of congenital anomalies beyond simply cataloging variants.
Similar grants
- OPEN Rural Community Health Integration2026 — New York State Department of Health
- OPEN FY26 Bureau of Land Management Rangeland Resource Management – Bureau wide — Bureau of Land Management
- OPEN FY26 Bureau of Land Management Cultural and Paleontological Resource Management – Bureau wide — Bureau of Land Management
- OPEN FY26 Bureau of Land Management Youth Conservation Corps – Bureau wide — Bureau of Land Management
- OPEN Infertility Training Center — Office of the Assistant Secretary for Health